DISEASE INDICATIONS:
Alagille syndrome

MANUFACTURER:
Mirum Pharmaceuticals

USAGE:
Oral

MEDICINE APPROVED BY:

European Medical Agency (EMA)

Food and Drug Administration (FDA)

Livmarli (maralixibat) is an oral solution approved by the U.S. FDA to treat cholestatic pruritus in patients with Alagille syndrome (ALGS) who are 1 year of age or older.